Mylan Laboratories Ltd Stock Analysis

BSE: 524794 | NSE: MATRIXLABS | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - Make an Informed Decision on Mylan Laboratories

M-Cap below 100cr DeciZen not available

FAQ's

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Mylan Laboratories:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide
Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20TTM
ROCE % 20.8%18%15.4%8.9%2.1%1.2%-0.4%-0.2%0.2%4.2%-
Value Creation Index 0.50.30.1-0.4-0.9-0.9-1.0-1.0-1.0-0.7-

Growth Parameters

Growth Parameters Colour Code Guide
Sales 2,8533,9525,3926,9787,8579,4679,6239,63810,96912,23912,239
YoY Gr. Rt. %-38.5%36.4%29.4%12.6%20.5%1.6%0.2%13.8%11.6%-
Adj EPS 26.129.233.326.8-8.7-13.3-27.4-24.6-22.32.811.6
YoY Gr. Rt. %-12.2%13.9%-19.7%-132.7%NANANANANA-
BVPS (₹) 104.5118.6159.1226.2239.8280.3333.2316294.7289.956.7
Adj Net Profit 408457521494-165-323-667-598-54268.1182
Cash Flow from Ops. 13950.13513846792561,6052,1011,3251,686-
Debt/CF from Ops. 624.25.117.210.342.85.84.16.55.1-

CAGR

CAGR Colour Code Guide
9 Years 5 Years 3 Years 1 Years
Sales 17.6%9.3%8.4%11.6%
Adj EPS -22%NANANA
BVPS 123.9-4.5-1.6
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide
Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20TTM
Return on Equity % 29.326.22414.8-3.7-5.6-8.9-7.6-7.316.7
Op. Profit Mgn % 2119.718.616.912.713.315.3191618.620.1
Net Profit Mgn % 14.311.69.77.1-2.1-3.4-6.9-6.2-4.90.61.5
Debt to Equity 0.50.70.71.61.51.61.11.11.21.2-
Working Cap Days 1962322392743553603643593443290
Cash Conv. Cycle 98102991121521621992011871920

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Mylan Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 11.6 -30
TTM Sales (₹ Cr.) 12,239 9,623
BVPS (₹.) 56.7 41.8
Reserves (₹ Cr.) 855 622
P/BV 3.69 5.01
PE 18.02 0.00
From the Market
52 Week Low / High (₹) 208.80 / 211.00
All Time Low / High (₹) 0.42 / 312.80
Market Cap (₹ Cr.) 3,273
Equity (₹ Cr.) 31.3
Face Value (₹) 2
Industry PE 38.1

Management X-Ray of Mylan Laboratories :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Analyst's Notes

News

About Mylan Laboratories Ltd

Matrix Laboratories (MLL), incorporated in the year 1985, is a subsidiary of US based company Mylan Inc. It is engaged in manufacturing of Active Pharmaceutical Ingredients (APIs) and Solid Oral Dosage Forms.

MLL has manufacturing facilities located in four locations in Hyderabad and Visakhapatnam, here it manufactures wide range of APIs. The company also has solid oral dosage forms facility located in Nashik. All its manufacturing plants are approved by US FDA, EDQM -EU, TGA (Australia) and has also received ISO-9000, ISO 14000 certifications. One of the core business activities of MLL is research and development of new APIs. It also offers contract research and development services for earlier stages of development and contract manufacturing for projects that have advanced further into development and are being considered for commercial manufacturing.

Mylan Inc had acquired 71.5% stake in Matrix Laboratories in 2007 for USD 736 million. Since then, the US firm has successfully integrated the two organisations, along with the generics business of Merck KGaA, to build a global, high quality pharmaceutical platform with $5.5 billion revenues in 2010.

Products

Matrix Laboratories is one of the world’s largest manufacturers and suppliers of active pharmaceutical ingredients (APIs) for a wide range of therapeutic categories, including antibacterials, central nervous system agents, antihistamine/anti-asthmatics, cardiovasculars, antivirals, antidiabetics, antifungals, proton pump inhibitors and pain management drugs.

Milestones

August 2009 - Matrix becomes a privately held Mylan subsidiary

June 2009 - Mylan announces successful Matrix delisting offer

January 2007 - Mylan Laboratories acquires a 71.5% controlling interest in Matrix Laboratories Limited

January 2007 - Matrix receives “Fastest Wealth Creator' award in Motilal Oswal Wealth Creation Study for 2006

May 2006 - Matrix receives “Best Management” award from the government of Andhra Pradesh

December 2005 - Matrix receives 'Fastest Wealth Creator' award in Motilal Oswal Wealth Creation Study for 2005

December 2005 - Matrix announces decision to acquire controlling stake in Concord Biotech, an Ahmedabad-based biotechnology company with fermentation and bio-catalytic technology capabilities and U.S. Food and Drug Administration (FDA) approved API manufacturing facilities

November 2005 - Matrix receives the National Award for R&D Efforts in Industry for 2005 in Pharmaceuticals/Chemical Sector from the Department of Scientific & Industrial Research, Government of India, Ministry of Science and Technology

June 2005 - Matrix Laboratories Limited acquires a controlling stake in Docpharma, based in Belgium

April 2005 - Matrix and Aspen Pharmacare Holdings Limited form joint ventures in India and South Africa

February 2005 - Matrix announces strategic alliance with MCHEM Pharma Group of China

January 2005 - Matrix receives 'Fastest Wealth Creator' award in Motilal Oswal Wealth Creation Study for 2004

January 2005 - Matrix purchases finished dosage facility located near Nashik, about 150 km from Mumbai

April 2004 - Matrix signs definitive agreements with India Newbridge Investments Limited and Maxwell (Mauritius) Pte. Limited

March 2004 - Matrix’s Board of Directors approves the company’s merger with Vera Laboratories Limited, Fine Drugs and Chemicals Limited, Medikon Laboratories Limited and Calibre Engineering Private Limited

March 2004 - Matrix receives U.S. FDA approval for its manufacturing facility at Jeedimetla, near Hyderabad

November 2003 - Matrix sets up two 50:50 joint venture companies, one in India and the other in Ireland

October 2003 - Matrix signs an agreement with the William J. Clinton Foundation to supply ARVs for the treatment of HIV/AIDS patients in sub-Saharan Africa, South Africa and the Caribbean countries

May 2003 - Matrix merges with Vorin Laboratories Limited and Medicorp Technologies India Limited

April 2003 - Matrix successfully files process patent applications for four products at the Indian Patent Office

Awards

In the year 2006 the company received “Best Management Award” from the Government of Andhra Pradesh

It received National Award for R&D Efforts in Industry in Pharmaceuticals /Chemical Sector from the Department of Scientific & Industrial Research, Government of India, Ministry of Science and Technology in 2005.

Read More Read Less